Free Trial
TSE:FRX

Fennec Pharmaceuticals (FRX) Stock Price, News & Analysis

Fennec Pharmaceuticals logo
C$13.31 +0.66 (+5.22%)
As of 05/15/2026 03:55 PM Eastern

About Fennec Pharmaceuticals Stock (TSE:FRX)

Advanced

Key Stats

Today's Range
C$12.85
C$13.78
50-Day Range
C$8.10
C$13.31
52-Week Range
C$7.59
C$13.83
Volume
2,483 shs
Average Volume
1,230 shs
Market Capitalization
C$462.03 million
P/E Ratio
N/A
Dividend Yield
2.02%
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

Fennec Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
1st Percentile Overall Score

FRX MarketRank™: 

Fennec Pharmaceuticals scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Fennec Pharmaceuticals is -39.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Fennec Pharmaceuticals is -39.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Fennec Pharmaceuticals has a P/B Ratio of 12.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for FRX.
  • Dividend Yield

    Fennec Pharmaceuticals pays a meaningful dividend of 2.02%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Fennec Pharmaceuticals does not have a long track record of dividend growth.

  • Read more about Fennec Pharmaceuticals' dividend.
  • News Sentiment

    Fennec Pharmaceuticals has a news sentiment score of -0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Fennec Pharmaceuticals this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Fennec Pharmaceuticals insiders have sold 67.96% more of their company's stock than they have bought. Specifically, they have bought C$48,052.00 in company stock and sold C$80,706.00 in company stock.

  • Percentage Held by Insiders

    16.20% of the stock of Fennec Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    12.41% of the stock of Fennec Pharmaceuticals is held by institutions.

  • Read more about Fennec Pharmaceuticals' insider trading history.
Receive FRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

FRX Stock News Headlines

Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Headlines

FRX Stock Analysis - Frequently Asked Questions

Fennec Pharmaceuticals' stock was trading at C$10.60 at the start of the year. Since then, FRX shares have increased by 25.6% and is now trading at C$13.31.

Fennec Pharmaceuticals Inc. (TSE:FRX) posted its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.10. Fennec Pharmaceuticals had a negative net margin of 17.22% and a negative trailing twelve-month return on equity of 58.09%.

Shares of FRX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fennec Pharmaceuticals investors own include Tilray Brands (TLRY), Aurora Cannabis (ACB), Encanto Potash (EPO), Adherex Technologies (FENC), Ocugen (OCGN), Passport Potash (PPI) and Workhorse Group (WKHS).

Company Calendar

Last Earnings
11/07/2024
Today
5/16/2026

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
TSE:FRX
CIK
N/A
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
C($0.34)
Trailing P/E Ratio
N/A
Forward P/E Ratio
22.04
P/E Growth
N/A
Net Income
-C$800.44 thousand
Net Margins
-17.22%
Pretax Margin
N/A
Return on Equity
-58.09%
Return on Assets
8.88%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.98
Quick Ratio
10.17

Sales & Book Value

Annual Sales
C$44.64 million
Price / Sales
10.35
Cash Flow
C$1.14 per share
Price / Cash Flow
11.66
Book Value
C$1.09 per share
Price / Book
12.16

Miscellaneous

Outstanding Shares
34,713,000
Free Float
N/A
Market Cap
C$462.03 million
Optionable
Not Optionable
Beta
3.22
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (TSE:FRX) was last updated on 5/16/2026 by MarketBeat.com Staff.
From Our Partners